Newsletter

Subscribe and receive updates on this company

Text STOCKS to 72727 for mobile alerts

We are excited to present Cocrystal Pharma, Inc. (OTC: COCP).

Full DD Report for COCP

Recent News from (OTC: COCP)

Cocrystal Pharma Receives FDA Clearance to Initiate Phase 2a Clinical Study Evaluating CC-31244 for the Treatment of Hepatitis C Virus
– Company on track to commence patient enrollment and dosing in Q2 2018 – – Topline data from Phase 2a study expected in Q4 2018 – ATLANTA, GA and BOTHELL, WA, April 03, 2018 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (NASDAQ: COCP), (“Cocrystal...
Source: GlobeNewswire
Date: April, 03 2018 08:00
Cocrystal Pharma Reports 2017 Financial Results and Provides Corporate Overview and Business Outlook
–Company successfully completes uplisting to the NASDAQ Capital Market – –Company positioned to achieve clinical and regulatory milestones over the course of 2018– ATLANTA, GA and BOTHELL, WA, March 22, 2018 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. &#x...
Source: GlobeNewswire
Date: March, 22 2018 07:05
Cocrystal Pharma Announces Uplist to The Nasdaq Capital Market
ATLANTA, GA and BOTHELL, WA, March 12, 2018 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (NASDAQ: COCP), (“Cocrystal” or the “Company”), a clinical stage biotechnology company discovering and developing novel antiviral therapeutics that target the replicatio...
Source: GlobeNewswire
Date: March, 12 2018 08:30
Cocrystal Pharma Provides Update on Reverse Stock Split
- Reverse stock split to be effective on Wednesday, January 24, 2018 on split-adjusted basis under trading symbol “COCPD” - ATLANTA, GA and BOTHELL, WA, Jan. 23, 2018 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (OTCQB: COCP), (“Cocrystal” or the “C...
Source: GlobeNewswire
Date: January, 23 2018 16:30
Cocrystal Pharma Announces 1-for-30 Reverse Stock Split
– Reverse stock split positions Company to uplist to the NASDAQ Capital Market in Q1 2018 – – Company expects to commence Phase 2a study in Q1 2018 for lead program, CC-31244, for the treatment of hepatitis C infection – – Company positioned to a...
Source: GlobeNewswire
Date: January, 23 2018 09:15
Cocrystal Pharma Announces Filing 2017 Third Quarter Financial Statements and Provides Company Update
ATLANTA, GA and BOTHELL, WA, Nov. 08, 2017 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (OTCQB: COCP), a company focused on developing novel antiviral therapeutics for human diseases, today announced the filing of its financial statements for the quarter ending September 30, 2017 and provided...
Source: GlobeNewswire
Date: November, 08 2017 17:30
Cocrystal Pharma to Present at the 2017 Cantor Fitzgerald Global Healthcare Conference in New York
ATLANTA, GA and BOTHELL, WA--(Marketwired - Sep 22, 2017) - Cocrystal Pharma, Inc. ( OTCQB : COCP ) today announced that Dr. Gary Wilcox and James Martin will be presenting a company overview at the Cantor Fitzgerald Global Healthcare Conference on Wednesday, September 27, 2017 at 8:35am in...
Source: Marketwired
Date: September, 22 2017 08:15
NetworkNewsBreaks - Top 10 Mid-day Percentage Gainers on September 5, 2017
Here is a list of stocks shaking up the markets today, with particular focus on NASDAQ and OTC small caps. The top gainers based on percentage: PEKN 68.15% – News: Purchases 80 gross acres in North Dakota MNKD 9.09% – News: Relocates corporate headquarters to Westlake Village...
Source: NetworkNewsWire
Date: September, 05 2017 12:00
Cocrystal Pharma, HitGen and InterX Enter into Drug Discovery Collaboration
ATLANTA, GA and BOTHELL, WA--(Marketwired - Sep 5, 2017) - Cocrystal Pharma, Inc. ( OTCQB : COCP ) today announced that it has entered into a research collaboration with HitGen, Ltd., a private biotechnology company and InterX, Inc., a private computer software company to develop small mole...
Source: Marketwired
Date: September, 05 2017 08:15
Cocrystal Pharma completes early-stage study of HCV candidate CC-31244; shares ahead 5%
Thinly traded nano cap Cocrystal Pharma ( OTCQB:COCP +5.4% ) perks up in early trading on the heels of its announcement of positive data from a Phase 1a/1b study assessing the safety, tolerability, pharmacokinetics and antiviral activity of HCV candidate CC-31244. More news on: Cocryst...
Source: SeekingAlpha
Date: August, 15 2017 10:06

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-04-213.843.603.843.605,657
2018-04-203.843.603.843.605,657
2018-04-193.8343.75013.8443.756,667
2018-04-183.913.803.97993.809,453
2018-04-174.013.9894.413.6935,666

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-03-094014,4369.0397Cover
2018-03-087825,20415.0269Cover
2018-03-073,1826,03052.7695Short
2018-03-065503,28416.7479Cover
2018-03-0520044345.1467Short

* Cover Mode

Short Analysis provided by Squeeze Report.


About Cocrystal Pharma, Inc. (OTC: COCP)

Logo for Cocrystal Pharma, Inc. (OTC: COCP)

Cocrystal is a clinical stage biotechnology company which develops novel medicines for use in the treatment of human viral diseases. Cocrystal has developed proprietary structure based drug design technology and antiviral nucleoside chemistry to create first in class and best in class antiviral drug candidates. Our focus is to pursue the development and commercialization of broad spectrum antiviral drug candidates that will transform the treatment and prophylaxis of hepatitis C, Influenza, and Norovirus. By concentrating our research and development efforts on viral replication inhibitors, we plan to leverage our infrastructure and expertise in these areas.

 

Contact Information

 

 

Current Management

  • Gary Wilcox / Interim CEO
  • Sam Lee / President
  • James J. Martin / CFO
  • Raymond Schinazi / Chairman
  • Gary Wilcox / Chairman
  • David Block /
  • Phillip Frost /
  • Jane H. Hsiao /
  • Steve Rubin /

Current Share Structure

  • Market Cap: $119,325,511 - 03/15/2018
  • Authorized: 800,000,000 - 03/06/2018
  • Issue and Outstanding: 24,402,444 - 03/06/2018

 


Recent Filings from (OTC: COCP)

Amendment to a previously filed 8-K
Filing Type: 8-K/AFiling Source: edgar
Filing Date: April, 09 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: April, 03 2018
Prospectus filed under Rule 424(b)(5)
Filing Type: 424B5Filing Source: edgar
Filing Date: April, 03 2018
Annual report with a comprehensive overview of the company
Filing Type: 10-KFiling Source: edgar
Filing Date: March, 21 2018
Notification that form 10-K will be submitted late
Filing Type: NT 10-KFiling Source: edgar
Filing Date: March, 19 2018
Registration of certain classes of securities 12(b) of the Securities Exchange Act
Filing Type: 8-A12BFiling Source: edgar
Filing Date: March, 09 2018
Filing Type: CERTFiling Source: edgar
Filing Date: March, 09 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: February, 14 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: February, 06 2018
Amendment to the SC 13G filing
Filing Type: SC 13G/AFiling Source: edgar
Filing Date: February, 02 2018

 

 


Daily Technical Chart for (OTC: COCP)

Daily Technical Chart for (OTC: COCP)


Stay tuned for daily updates and more on (OTC: COCP)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (OTC: COCP)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

The Subway Trader
@TheSubwayTrader

 

 


Disclaimer: The Subway Trader publishes reports providing information on selected companies. The Subway Trader is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. The Subway Trader accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in COCP is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. The Subway Trader has received up to $100,000 worth of crypto currency from a non-affiliated third party for the publication and circulation of this report. The Subway Trader does not own any shares of COCP and does not buy, sell, or trade any shares of COCP. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2016 by The Subway Trader. All rights reserved. Our Full Disclaimer: http://thesubwaytrader.com/disclaimer/

 

 

Release this Report to Investors

Via Email

Via Text

Important

If you would like to schedule the release please Contact Us and we will assist you otherwise we will release this report to investors 15 minutes after payment is received to allow the most current information to be updated before the report is sent. Interested in reaching more investors? Contact Us